SLU-PP-332: Exercise Mimetic Drug for Endurance and Fat Loss
Introduction: Developing SLU-PP-332 as an Exercise Mimetic
SLU-PP-332 is being called an "exercise in a pill"—and early research shows it might deliver. In mice, it boosts endurance, burns fat, and increases cellular energy—all without extra movement.
SLU-PP-332 is a synthetic molecule, also referred to as a "pan-agonist," that binds to and activates estrogen-related receptors (ERRs). These receptors—specifically ERRα (alpha), ERRβ (beta), and ERRγ (gamma)—effectively preserve the balance of energy in our cells. To maintain constant energy supply in the body, they control basic metabolic pathways like how lipids are burned, how glucose is used, and how mitochondria are generated.
Because these tissues have such high energy demands, you find the highest ERR expression in the brain, heart, and muscles. Activating these receptors with SLU-PP-332 increases mitochondrial activity and metabolic efficiency, enabling cells to function more like they do during exercise.
Watch: Understanding SLU-PP-332 and Exercise Mimetics
Key Research Findings
- Exercise mimetic: Triggers ERR receptors like physical exercise does
- Performance boost: In lab studies, mice ran 70% longer and 45% farther
- Lab doses: 100-2000 μg daily range in research settings
- Size: Small molecule, 290.32 MW
- Status: Available for research use only—not approved for human consumption
- Mechanism: Boosts mitochondria and energy output at the cellular level
Chemical Composition and Specifications of SLU-PP-332
SLU-PP-332 is a powerful and specific pan-estrogen-related receptor (ERR) activator that improves energy profiles in many tissues across the body. Researchers call it an exercise mimetic because it activates metabolic regulators more effectively than similar compounds.
Technical Specifications
Here is crucial scientific data concerning SLU-PP-332:
- IUPAC Name: (E)-4-Hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide
- Purity Standard: ≥98% (HPLC validated)
- CAS Registry Number: 303760-60-3
- Molecular Weight: 290.32 g/mol
- Solubility Profile: DMSO soluble up to 100 mM
- Storage Requirements: Store at -20°C after desiccation
- Research Classification: For laboratory research use only
How Does SLU-PP-332 Work?
SLU-PP-332 acts by selectively activating ERRs in metabolically active tissues throughout the body. As transcriptional regulators, these nuclear receptors influence the expression of genes relating to oxidative capability, mitochondrial function, and energy metabolism.
Cellular Effects of SLU-PP-332
The compound triggers several metabolic changes:
- Mitochondrial biogenesis: Cells produce more mitochondria (cellular powerhouses)
- Enhanced fat oxidation: Fatty acids get metabolized more efficiently
- Glucose regulation: Improved insulin response and steadier blood sugar
- Muscle fiber transformation: Shift toward slow-twitch fibers with greater endurance
Biological Activity and Receptor Potency
SLU-PP-332 demonstrates selective binding to ERR receptors with varying degrees of activity for each receptor subtype.
Receptor Binding Affinity
| Receptor Subtype | EC50 Value | Binding Affinity | Primary Tissue Expression |
|---|---|---|---|
| ERRα | 98 nM | Highest | Muscle, Heart, Kidney |
| ERRβ | 230 nM | Moderate | Brain, Kidney |
| ERRγ | 430 nM | Lower | Brain, Muscle, Heart |
Muscle Cell Response
When researchers tested SLU-PP-332 on muscle cells, they observed:
- Metabolic shift: Cells transitioned to more efficient oxidative metabolism
- Fat reduction: Decreased intramuscular fat accumulation
- Energy production: Enhanced mitochondrial ATP synthesis
Clinical Studies and Research Data
Preclinical Mouse Model Studies
Comprehensive preclinical studies on mice have provided strong data on the metabolic effects of SLU-PP-332:
- Metabolic syndrome improvements: Mice treated with SLU-PP-332 showed reduced body weight and fat mass even on an obesity-inducing diet, without changes in food intake or spontaneous activity
- Exercise performance enhancement: Treated animals demonstrated a 70% increase in running endurance and covered 45% more total distance compared to control groups
- Mitochondrial changes: Muscle tissue displayed increased mitochondrial density and higher expression of genes linked to oxidative metabolism
Dose-Response Relationships
Research reveals dose-dependent effects:
| Dosage Category | Daily Range | Observed Effects | Research Applications |
|---|---|---|---|
| Low Dose | 100–200 μg/day | Initial metabolic activation | Baseline studies |
| Standard Dose | 500–1000 μg/day | Significant fat oxidation | Metabolic research |
| High Dose | 1000–2000 μg/day | Maximum endurance effects | Performance studies |
SLU-PP-332 Exercise Benefits in Research
Metabolic Improvements
- Enhanced insulin sensitivity and glucose control
- Reduced blood lipids (triglycerides and free fatty acids)
- Improved muscle oxidative capacity
- Increased type I (endurance) muscle fiber composition
Cardiovascular Effects
- Enhanced cardiac fatty acid metabolism
- Reduced metabolic syndrome risk factors
- Improved cardiac mitochondrial function
Multi-System Benefits
- Kidney function: Reduced inflammation and improved metabolic efficiency
- Neuroprotection: Protection against oxidative stress
- Hormonal effects: Potential increases in DHEA-sulfate levels
Potential Therapeutic Applications
SLU-PP-332 for Weight Loss and Metabolic Health
Current research provides evidence of potential therapeutic applications for:
- Metabolic syndrome: Improvement of multiple metabolic parameters
- Type 2 diabetes: Enhanced glycemic control and insulin sensitivity
- Sarcopenia: Prevention of age-related muscle wasting through mitochondrial support
- Cardiovascular disease: Reduced risk factors and improved cardiac metabolism
- Mitochondrial disorders: Potential benefit for conditions affecting cellular energy production
Research Protocols and Stacking Guidelines
Research Dosing Protocols
- Initial phase: 100-200 μg/day for tolerance assessment
- Standard protocol: Gradually increase to 500-1000 μg/day based on research objectives
- Timing: Administration 30-60 minutes before testing or at consistent daily times
- Cycling: 8-week research periods followed by washout phases
Combination Research Strategies
Researchers have investigated combinations of compounds to enhance metabolic effects:
Synergistic Supplement Research
- NMN/NR: NAD+ boosters for enhanced cellular energy
- Alpha-Lipoic Acid: Mitochondrial support and glucose metabolism
- Forskolin: Fat burning and metabolic enhancement
- Thyroid support compounds: Overall metabolic rate optimization
- Quercetin/Fisetin: Cellular health and anti-aging support
Research Peptide Combinations
- FOX04-DRI: Senolytic effects for cellular rejuvenation
- BPC-157: Tissue repair and recovery enhancement
- TB-500: Regenerative support
- Epitalon: Circadian rhythm and telomere support
- AOD-9604: Targeted fat metabolism
- GHK-Cu: Skin health and anti-aging effects
- Semaglutide: Additional metabolic support
For comprehensive peptide combination strategies, see our detailed stacking guide.
Comprehensive Preclinical Data
SLU-PP-332 has been evaluated in various preclinical experiments, demonstrating its mechanism occurs via ERR activation across all three ERR isoforms. Key findings include increased energy expenditure, enhanced fatty acid oxidation, and significant amelioration of metabolic syndrome symptoms in animal models.
Research Availability
- Available exclusively for laboratory research
- Supplied with certificates of analysis
- Manufactured in quality-controlled facilities
- Order SLU-PP-332 for research: Available at PeptideHackers.com
Safety Profile and Important Considerations
Current Safety Data
- Human trials: Not yet conducted. While preclinical data appears promising, this compound has not undergone FDA approval processes. It remains strictly for laboratory research.
- Animal observations: Mild temperature elevation and occasional transient liver enzyme increases
- Research cycling: 8-week periods recommended with appropriate washout phases
- Monitoring parameters: Liver function, metabolic markers, and cardiovascular parameters in research settings
Future Research Directions
SLU-PP-332 represents an important development in exercise mimetic drug research, offering comprehensive understanding of how ERR activation controls metabolism. The ability to replicate exercise benefits at the cellular level creates opportunities for treating metabolic disorders and age-related conditions.
Future research priorities include human clinical trials, long-term safety evaluations, and expanded investigation of therapeutic applications. The scientific community continues to explore SLU-PP-332's potential to address metabolic diseases, enhance exercise capacity, and promote healthy aging.
Frequently Asked Questions
Is SLU-PP-332 legal?
Yes, SLU-PP-332 is legal for research purposes in most jurisdictions. However, it is not approved for human consumption and is strictly designated for laboratory research only.
Can SLU-PP-332 replace exercise?
While SLU-PP-332 mimics many cellular effects of exercise in laboratory studies, it cannot replicate all benefits of physical activity such as cardiovascular conditioning, bone density improvements, or mental health benefits. It's being studied as a potential therapeutic for those unable to exercise.
What are the side effects observed in animal studies?
In preclinical studies, researchers observed mild temperature elevation and occasional transient increases in liver enzymes. Long-term safety data in humans is not yet available as human trials have not been conducted.
Where can I buy SLU-PP-332 for research?
SLU-PP-332 is available from specialized research chemical suppliers. PeptideHackers.com offers high-purity SLU-PP-332 for legitimate research purposes with proper documentation.
What doses are used in research?
Research protocols typically use 100-2000 μg/day in animal models, with most studies employing 500-1000 μg/day as a standard dose. Human equivalent doses have not been established.
